6′7′-Dihydroxybergamottin contributes to the grapefruit juice effect

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 6, 2004, Pages 569-579

  Kakar, Shefali M ^b   Paine, Mary F ^b   Stewart, Paul W ^b   Watkins, Paul B ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; COMPLEMENTARY DNA; CYTOCHROME P450 3A4; FELODIPINE; FUROCOUMARIN DERIVATIVE; UNCLASSIFIED DRUG; 6',7'-DIHYDROXYBERGAMOTTIN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; PLANT EXTRACT; PSORALEN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CENTRIFUGATION; CHRONOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG INHIBITION; DRUG PURIFICATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FILTRATION; GRAPEFRUIT JUICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IMMUNOREACTIVITY; LIQUID CHROMATOGRAPHY; MALE; MEDICAL ASSESSMENT; ORANGE JUICE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; BEVERAGE; DRUG ANTAGONISM; FOOD DRUG INTERACTION; GRAPEFRUIT; METABOLISM; PHYSIOLOGY;

ADULT; AREA UNDER CURVE; BEVERAGES; CACO-2 CELLS; CITRUS PARADISI; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FELODIPINE; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; PLANT EXTRACTS; PSORALENS;

EID: 2942615086     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.02.007     Document Type: Article

References (22)

1. Bailey D.G., Arnold J.M.O., Spence J.D. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 46:1998;101-110
2. Lown K.S., Bailey D.G., Fontana R.J., Janardan S.K., Adair C.H., Fortlage L.A., et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. [see comments] J Clin Invest. 99:1997;2545-2553
3. Edwards D.J., Bellevue F.H., Woster P.M. Identification of 6′, 7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos. 24:1996;1287-1290
4. Fukuda K., Ohta T., Oshima Y., Ohashi N., Yoshikawa M., Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice furocoumarin dimers as components of drug interaction. Pharmacogenetics. 7:1997;391-396
5. He K., Iyer K.R., Hayes R.N., Sinz M.W., Woolf T.F., Hollenberg P.F. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 11:1998;252-259
6. Tassaneeyakul W., Guo L.Q., Fukuda K., Ohta T., Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys. 378:2000;356-363
7. Guo L.Q., Fukuda K., Ohta T., Yamazoe Y. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos. 28:2000;766-771
8. Schmiedlin-Ren P., Edwards D.J., Fitzsimmons M.E., He K., Lown K.S., Woster P.M., et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos. 25:1997;1228-1233
9. Fukuda K., Guo L., Ohashi N., Yoshikawa M., Yamazoe Y. Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction. J Chromatogr B Biomed Sci Appl. 741:2000;195-203
10. Malhotra S., Bailey D.G., Paine M.F., Watkins P.B. Seville orange juice-felodipine interaction comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 69:2001;14-23
11. Edwards D.J., Fitzsimmons M.E., Schuetz E.G., Yasuda K., Ducharme M.P., Warbasse L.H., et al. 6', 7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther. 65:1999;237-244
12. Bailey D.G., Kreeft J.H., Munoz C., Freeman D.J., Bend J.R. Grapefruit juice-felodipine interaction effect of naringin and 6′, 7′-dihydroxybergamottin in humans. Clin Pharmacol Ther. 64:1998;248-256
13. Eagling V.A., Profit L., Back D.J. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 48:1999;543-552
14. 3. Mol Pharmacol. 51:1997;741-754
15. 3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab Dispos. 29:2001;1446-1453
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275
17. Bailey D.G., Bend J.R., Arnold J.M.O., Tran L.T., Spence J.D. Erythromycin-felodipine interaction magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther. 60:1996;25-33
18. Ohnishi A., Matsuo H., Yamada S., Takanaga H., Morimoto S., Shoyama Y., et al. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br J Pharmacol. 130:2000;1369-1377
19. Bailey D.G., Dresser G.K., Bend J.R. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity comparison with grapefruit juice. Clin Pharmacol Ther. 73:2003;529-537
20. Takanaga H., Ohnishi A., Murakami H., Matsuo H., Higuchi S., Urae A., et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther. 67:2000;201-214
21. Takanaga H., Ohnishi A., Matsuo H., Murakami H., Sata H., Kuroda K., et al. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol. 49:2000;49-58
22. Lilja J.J., Kivisto K.T., Neuvonen P.J. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther. 68:2000;384-390